Evaluation Of Isoniazid Preventive Therapy Policy

Authors

  • Bhavesh Modi John Hopkins University, USA
  • Paresh Dave Government of Gujarat, Gandhinagar

Keywords:

Tuberculosis, Isoniazide Preventive Therapy, National Program, HIV/AIDS

Abstract

NA

References

WHO. Global tuberculosis control: 2011 Report. October 2011. Geneva, Switzerland, World Health Organization, 2011.Retrieved on November 23, 2011 from http://www.who.int/tb/publications/global_report/2 011/gtbr11_full.pdf

Getahun H et al. HIV infection associated tuberculosis: the epidemiology and the response. Clinical Infectious Diseases, 2010, 50:S201–S207; doi:10.1086/651492. Retrieved on November 23, 2011, from http://cid.oxfordjournals.org/content/50/Supplement

_3/S201.full.pdf+html

UNAIDS report on the Global AIDS Epidemic, 2010 Retrieved on November 23, 2011 from http://www.unaids.org/globalreport/documents/201 01123_GlobalReport_full_en.pdf

United States President’s Emergency Plan for AIDS Relief Retrieved on November 23, 2011 from http://www.pepfar.gov

Global Fund to Fight AIDS, Tuberculosis and Malaria Retrieved on November 23, 2011 from http://www.theglobalfund.org/en

Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda–Case Western Reserve University Research Collaboration N Engl J Med 1997;337:801–8. doi:10.1056/NEJM199709183371201 PMID:9295239

de Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS 2001;15:2129–35. doi:10.1097/00002030-200111090-00008 PMID:11684932

Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH et al.Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786–92. doi:10.1016/S0140-6736(97)06532-X PMID:9519950

Pape JW, Jean SS, Ho JL, Hafner A, Johnson W. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268–72. doi:10.1016/0140-6736(93)91817-6 PMID:8101302

Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala B et al.Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447–57. doi:10.1097/00002030-199818000-00014 PMID:9875583

Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL et al.A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997;337:315–20. doi:10.1056/NEJM199707313370505 PMID:9233868

Bucher HC, Griffith LE, Guyat GH, Sudre P, Naef M, Sendi P et al.Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999;13:501–7. doi:10.1097/00002030-199903110-00009 PMID:10197379

Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst Rev 2004:CD000171. PMID:14973947

Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS et al.The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007;21:1441–8. doi:10.1097/QAD. 0b013e328216f441 PMID:17589190

Policy statement on preventive therapy against tuberculosis in people living with HIV. Geneva: World Health Organization; 1998 (WHO/TB/98.255). Retrieved on November 23, 2011 from http://whqlibdoc.who.int/hq/1998/WHO_TB_98.255. pdf

Consensus statement of the core group of TB/HIV Working Group of STOP TB partnership. Geneva: Stop TB partnership. Retrieved on November 23, 2011 from http://www.stoptb.org/wg/tb_hiv/assets/documents/IPT%20Consensus%20Statement%20TB%20HIV%20C ore%20Group.pdf

Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. Geneva: World Health Organization; 2008. Retrieved on November 23, 2011 from http://www.who.int/hiv/pub/prev_care/OMS_EPP_ AFF_en.pdf

Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva, World Health Organization, 2010. Retrieved on November 23, 2011 from

http://whqlibdoc.who.int/publications/2011/9789241 500708_eng.pdf

Getahun H et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource constrained settings: individual participant data meta-analysis of observational studies. PLoS Medicine, 2011, 8(1) e1000391 (doi:10.1371/journal.pmed).

World Health Organization. Global tuberculosis control report: 2010 Geneva, Switzerland: 2010. Report No. WHO/HTM/TB/2010.7. Retrieved on November 23, 2011 from

http://whqlibdoc.who.int/publications/2010/9789241 564069_eng.pdf

Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings Lancet Infect, 2009, Dis 9: 173– 184.

Getahun H, Harrington M, O’Brien R, Nunn P. Diagnosis of smear negative pulmonary tuberculosis in people with HIV infection or AIDS in resource- constrained settings: informing urgent policy changes. Lancet, 2007, 369:2042–2049.

Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12:744–751.

Van Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJ, Churchyard GJ, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010; 24:1051–1055.

Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M.Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J TB Lung Dis 2008; 12:498–505.

Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, et al. Barriers to implementation of Isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS 2010; 24 (suppl 5):S45– S48.

World Health Organization. Scaling up prevention and treatment for TB and HIV: report of the Fourth Global TB/HIV Working Group meeting. Geneva: WHO Press; 2005. Report

No. WHO/HTM/TB/2005.348.

Getahun H, Granich R, Sculier D, Gunnerberg C, Blank L, Nunn P, Raviglione M. Implementation of Isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 2010, 24 (suppl 5):S57-S65.

Date AA, Vitoria M, Granich R, Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole prophylaxis and Isoniazid preventive therapy for people living with HIV. Bulletin World Health Organization 2010; 88:253– 259.

Downloads

Published

2012-03-31

How to Cite

1.
Modi B, Dave P. Evaluation Of Isoniazid Preventive Therapy Policy. Natl J Community Med [Internet]. 2012 Mar. 31 [cited 2024 Apr. 25];3(01):171-5. Available from: https://njcmindia.com/index.php/file/article/view/1671

Issue

Vol. 3 No. 01 (2012)

Section

Review Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.